Caxton Associates LP purchased a new stake in Globus Medical Inc (NYSE:GMED) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 15,400 shares of the medical device company’s stock, valued at approximately $458,000.

Other hedge funds have also added to or reduced their stakes in the company. SG Americas Securities LLC raised its position in Globus Medical by 19.9% during the 2nd quarter. SG Americas Securities LLC now owns 47,862 shares of the medical device company’s stock worth $1,587,000 after buying an additional 7,937 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Globus Medical by 26.2% during the 2nd quarter. Goldman Sachs Group Inc. now owns 166,090 shares of the medical device company’s stock worth $5,505,000 after buying an additional 34,513 shares during the last quarter. Retirement Systems of Alabama raised its position in Globus Medical by 45.6% during the 3rd quarter. Retirement Systems of Alabama now owns 135,562 shares of the medical device company’s stock worth $4,029,000 after buying an additional 42,481 shares during the last quarter. Vanguard Group Inc. raised its position in Globus Medical by 1.4% during the 2nd quarter. Vanguard Group Inc. now owns 5,712,043 shares of the medical device company’s stock worth $189,355,000 after buying an additional 76,345 shares during the last quarter. Finally, AJO LP purchased a new position in Globus Medical during the 2nd quarter worth $1,262,000. Hedge funds and other institutional investors own 72.20% of the company’s stock.

GMED has been the subject of a number of analyst reports. BidaskClub upgraded shares of Globus Medical from a “hold” rating to a “buy” rating in a research report on Tuesday, November 14th. Bank of America upgraded shares of Globus Medical from an “underperform” rating to a “neutral” rating in a research report on Friday, November 10th. ValuEngine downgraded shares of Globus Medical from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. BTIG Research restated a “buy” rating and set a $37.00 price objective on shares of Globus Medical in a research report on Thursday, November 9th. Finally, Needham & Company LLC restated a “hold” rating on shares of Globus Medical in a research report on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $36.83.

In related news, insider A Brett Murphy sold 51,449 shares of the stock in a transaction dated Thursday, November 9th. The shares were sold at an average price of $35.00, for a total value of $1,800,715.00. Following the sale, the insider now directly owns 49,768 shares of the company’s stock, valued at approximately $1,741,880. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director David D. Davidar sold 55,383 shares of the stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $40.66, for a total transaction of $2,251,872.78. Following the completion of the sale, the director now directly owns 752,236 shares in the company, valued at $30,585,915.76. The disclosure for this sale can be found here. Corporate insiders own 28.21% of the company’s stock.

Globus Medical Inc (NYSE GMED) opened at $38.99 on Thursday. Globus Medical Inc has a 12 month low of $23.44 and a 12 month high of $41.70. The firm has a market cap of $3,703.73, a price-to-earnings ratio of 30.74, a PEG ratio of 2.92 and a beta of 0.58.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Wednesday, November 8th. The medical device company reported $0.30 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.30. Globus Medical had a net margin of 17.54% and a return on equity of 13.67%. The business had revenue of $151.74 million for the quarter, compared to analysts’ expectations of $150.73 million. During the same period in the prior year, the company posted $0.29 EPS. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. research analysts predict that Globus Medical Inc will post 1.27 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/caxton-associates-lp-purchases-shares-of-15400-globus-medical-inc-gmed/1763518.html.

Globus Medical Profile

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Institutional Ownership by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.